TrialBlood2015

Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias.

Nicole Kucine et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.